Experimental therapies in the treatment of cutaneous T-cell lymphoma.
Although meaningful clinical responses have been demonstrated in cutaneous T-cell lymphoma using a number of therapeutic modalities, survival benefits have not been demonstrated for the majority of patients. Several novel therapies, including retinoids, purine analogs, biologic response modifiers, monoclonal antibodies, and fusion toxins have demonstrated activity and clinical promise in early studies.
Boston University Medical Center, Massachusetts, USA.
F M
FM
Foss
T M
TM
Kuzel
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000628:therapy*; D011687:Purines / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012176:Retinoids / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000628:therapy*; D016305:Thymopentin / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D011687:Purines; D011993:Recombinant Fusion Proteins; D012176:Retinoids; D016305:Thymopentin